RU96124084A - TRANSDERMAL ADMINISTRATION OF ANTIEPILEPTIC DRUGS - Google Patents

TRANSDERMAL ADMINISTRATION OF ANTIEPILEPTIC DRUGS

Info

Publication number
RU96124084A
RU96124084A RU96124084/14A RU96124084A RU96124084A RU 96124084 A RU96124084 A RU 96124084A RU 96124084/14 A RU96124084/14 A RU 96124084/14A RU 96124084 A RU96124084 A RU 96124084A RU 96124084 A RU96124084 A RU 96124084A
Authority
RU
Russia
Prior art keywords
ethanol
water
drug administration
pharmaceutically acceptable
esters
Prior art date
Application number
RU96124084/14A
Other languages
Russian (ru)
Other versions
RU2152784C1 (en
Inventor
Вейбель Хелле
Бонне Эриксен Петер
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU96124084A publication Critical patent/RU96124084A/en
Application granted granted Critical
Publication of RU2152784C1 publication Critical patent/RU2152784C1/en

Links

Claims (11)

1. Система трансдермального введения лекарственных препаратов, включающая один или более усилителей проникающей способности и соединение, отобранное из тиагабина, его фармацевтически приемлемых солей, фармацевтически приемлемых C1-6-алкилэфиров или ионных пар тиагабина и салициловой или олеиновой кислоты.1. A transdermal drug administration system comprising one or more penetration enhancers and a compound selected from tiagabin, its pharmaceutically acceptable salts, pharmaceutically acceptable C 1-6 alkyl esters or ion pairs of tiagabin and salicylic or oleic acid. 2. Система введения лекарственных препаратов по п. 1, в которой фармацевтически приемлемыми являются его ацетат, бензоат, фумарат. фосфат, малат, малеат, манделат, месилат, лактат, салицилат, сульфат, тартрат, сукцинат, гидрохлорид и гидраты. 2. The drug administration system of claim 1, wherein its acetate, benzoate, fumarate are pharmaceutically acceptable. phosphate, malate, maleate, mandelate, mesylate, lactate, salicylate, sulfate, tartrate, succinate, hydrochloride and hydrates. 3. Система введения лекарственных препаратов по пп. 1 или 2, в которой усилитель проникающей способности отобран из группы, состоящей из насыщенных и ненасыщенных жирных кислот и их эфиров в пропиленгликоле, бесабололе в этаноле/воде, цинеола в этаноле/воде, гидроксипропил-β-циклодекстрина в этаноле/воде или децилметилсульфоксида в этаноле/воде. 3. The system of administration of drugs according to paragraphs. 1 or 2, in which the penetration enhancer is selected from the group consisting of saturated and unsaturated fatty acids and their esters in propylene glycol, non-alcohol in ethanol / water, cineole in ethanol / water, hydroxypropyl-β-cyclodextrin in ethanol / water or decyl methyl sulfoxide in ethanol / water. 4. Система введения лекарственных препаратов по любому из пп. 1-3, в которой указанное соединение вводится в количестве приблизительно от 0,01 мг до 10,0 мг на 1 кг веса тела в сутки. 4. The system of administration of drugs according to any one of paragraphs. 1-3, in which the specified compound is administered in an amount of from about 0.01 mg to 10.0 mg per 1 kg of body weight per day. 5. Система введения лекарственных препаратов по п. 1, в которой усилитель проникающей способности и соединение диспергированы в матрице. 5. The drug administration system of claim 1, wherein the penetration enhancer and compound are dispersed in the matrix. 6. Система введения лекарственных препаратов по п. 3, в которой усилителем проникающей способности является олеиновая кислота в пропиленгликоле. 6. The drug administration system of claim 3, wherein the penetrating agent is oleic acid in propylene glycol. 7. Система введения лекарственных препаратов по п. 3, в которой усилителем проникающей способности является бисаболол в этаноле/воде. 7. The drug administration system of claim 3, wherein the penetration enhancer is bisabolol in ethanol / water. 8. Система введения лекарственных препаратов по п. 3, в которой усилителем проникающей способности является децилметилсульфоксид в этаноле/воде. 8. The drug administration system of claim 3, wherein the penetration enhancer is decyl methyl sulfoxide in ethanol / water. 9. Способ усиления проникающей способности через кожу и оболочки человека и животных соединения, отобранного из тиагабина и его фармацевтически приемлемых солей и эфиров, включающий использование усилителя проникающей способности, отобранного из группы, состоящей из насыщенных и ненасыщенных жирных кислот и их эфиров в пропиленгликоле, бисаболола в этаноле/воде, цинеола в этаноле/воде, гидроксипропил -β- циклодекстрина в этаноле/воде или децилметилсульфоксида в этаноле/воде. 9. A method of enhancing penetration through the skin and membranes of humans and animals of a compound selected from tiagabin and its pharmaceutically acceptable salts and esters, comprising the use of a penetration enhancer selected from the group consisting of saturated and unsaturated fatty acids and their esters in propylene glycol, bisabolol in ethanol / water, cineole in ethanol / water, hydroxypropyl-β-cyclodextrin in ethanol / water or decylmethyl sulfoxide in ethanol / water. 10. Способ лечения эпилепсии, включающий трансдермальное введение эффективного количества соединения, отобранного из тиагабина и его фармацевтически приемлемых солей и эфиров. 10. A method of treating epilepsy, comprising transdermal administration of an effective amount of a compound selected from tiagabin and its pharmaceutically acceptable salts and esters. 11. Способ по п. 9, в котором указанное соединение вводится в количестве приблизительно от 0,01 до 10,0 мг на 1 кг веса тела в сутки. 11. The method of claim 9, wherein said compound is administered in an amount of about 0.01 to 10.0 mg per 1 kg of body weight per day.
RU96124084/14A 1994-05-20 1995-05-17 Method for making transdermal injections of antiepileptic preparations RU2152784C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK57794 1994-05-20
DK0577/94 1994-05-20

Publications (2)

Publication Number Publication Date
RU96124084A true RU96124084A (en) 1999-01-20
RU2152784C1 RU2152784C1 (en) 2000-07-20

Family

ID=8095138

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96124084/14A RU2152784C1 (en) 1994-05-20 1995-05-17 Method for making transdermal injections of antiepileptic preparations

Country Status (20)

Country Link
US (1) US5750140A (en)
EP (1) EP0760656A1 (en)
JP (1) JPH10500415A (en)
KR (1) KR970703146A (en)
CN (1) CN1148806A (en)
AU (1) AU698131B2 (en)
BR (1) BR9507736A (en)
CA (1) CA2190837C (en)
CZ (1) CZ338196A3 (en)
FI (1) FI964619A0 (en)
HU (1) HUT75864A (en)
IL (1) IL113793A (en)
NO (1) NO964915L (en)
NZ (1) NZ287012A (en)
PE (1) PE2596A1 (en)
RU (1) RU2152784C1 (en)
SK (1) SK281076B6 (en)
TW (1) TW372875B (en)
WO (1) WO1995031976A1 (en)
ZA (1) ZA954118B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
GB9712272D0 (en) * 1997-06-12 1997-08-13 Procter & Gamble Cosmetic composition
US6537537B2 (en) 1997-06-12 2003-03-25 The Procter & Gamble Company Water-in-silicone emulsion cosmetic compositions
US6316010B2 (en) 1997-06-12 2001-11-13 The Procter & Gamble Company Cosmetic compositions
GB9712271D0 (en) * 1997-06-12 1997-08-13 Procter & Gamble Cosmetic composition
GB9712269D0 (en) * 1997-06-12 1997-08-13 Procter & Gamble Cosmetic composition
PT991409E (en) * 1997-08-01 2002-06-28 Elan Corp Plc COMPOSITIONS OF CONTROLLED LIBERATION CONTAINING TIAGABINE
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
FR2771292B1 (en) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques TIAGABINE-CONTAINING SPHEROIDS, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS
WO2003080072A1 (en) * 2002-03-18 2003-10-02 Cady Roger K Preemptive prophylaxis of migraine
AR112480A1 (en) 2017-08-24 2019-10-30 Novo Nordisk As COMPOSITIONS OF GLP-1 AND ITS USES
AU2021208601A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105990B (en) * 1981-08-27 1985-06-19 Nitto Electric Ind Co Adhesive skin patches
SE8904296D0 (en) * 1989-12-21 1989-12-21 Pharmacia Ab TRANSDERMAL SYSTEM
DK58291D0 (en) * 1991-04-02 1991-04-02 Novo Nordisk As CRYSTALINE MATERIAL AND ITS PREPARATION

Similar Documents

Publication Publication Date Title
KR100764156B1 (en) Intradermal-penetration agents for topical local anesthetic administration
US5057500A (en) Treatment of pruritis with esters and amides
EP0261429B1 (en) Penetration enhancement systems and the preparation thereof
JP2022060428A (en) Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
ES2673219T3 (en) Composition for transdermal delivery of active agents
RU2381794C2 (en) Local composition containing ambroxol
EP0098743A1 (en) Phenyl alpha-acyloxyacetamide derivates and their therapeutic use
JP2001502693A (en) Permeation enhancers suitable for transdermal drug administration compositions, devices, and methods
RU96124084A (en) TRANSDERMAL ADMINISTRATION OF ANTIEPILEPTIC DRUGS
JP2007536312A (en) Permeability enhancing composition for anticholinergics
KR20080071185A (en) Pharmaceutical compositions comprising buprenorphine
RU2004106779A (en) METHOD FOR PREVENTION AND / OR TREATMENT OF DYSFUNCTION AND / OR DISORDERS OF NAIL STRUCTURE, PLASTER FOR ITS IMPLEMENTATION AND ITS APPLICATION
JPH02503672A (en) Fatty acids and their short chain esters as penetration enhancers in aqueous systems
US4263313A (en) Topical pharmaceutical formulations, carrier compositions therefor, and preparation thereof
RU2001111868A (en) ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLUR5) FOR THE TREATMENT OF PAIN AND STATE OF ALARM
JP2000515498A (en) Topical composition comprising a combination of an antihistamine compound and a terpenoid compound
JPS60152413A (en) Composition for local application with improved percutaneousdrug release by menthol
DE102005013726A1 (en) Transdermal therapeutic system for transdermal application of opioid containing analgesics, especially using a plaster for application to permit long-term, pain-free application
JPH08175986A (en) Pharmaceutical composition containing 5-aminolevulinic acid exhibiting percutaneous activity
CN1430513A (en) Topical formulations for the transdermal delivery of niacin and method of treating hyperlipidemia
JPH04128231A (en) Method of treating addiction to cocaine or heroin comprising percutaneously delivering buprenorphine
US7413748B2 (en) Transdermal buprenorphine to treat pain in sickle cell crisis
JPH0640947A (en) Composition for percutaneous absorption preparation and percutaneous absorption preparation
WO2001003774A2 (en) Pharmaceutical composition for the treatment of calcification
JP2005089345A (en) Therapeutic agent for insect bite and sting